ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
ImmVira's MVR-T3011 IV completed first 2 cohorts dose-escalation of U.S. Phase I clinical study with favorable safety data
January 19, 2022ImmVira's breakthrough product MVR-T3011 IV, global first clinical-stage oncolytic herpes simplex virus (oHSV) via intravenous injection, has recently completed first 2 cohorts dose-escalation of U.S. Phase I clinical study... -
ImmVira's MVR-T3011 Obtained NMPA's Approval for Intravenous Administration (IV) Phase I Clinical Trial
August 10, 2021ImmVira announced that as a global first, its lead oncolytic virus therapy program MVR-T3011 IV (also known as T3011), obtained approval from National Medical Products Administration for clinical trial for treatments using intravenous administration ...
Pharma Sources Insight January 2025
